Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x100px

Document › Details

Merck KGaA. (4/20/17). "Press Release: Merck Provides Upgraded Manufacturing Capabilities to BioInvent with Single-use Mobius Bioreactors". Darmstadt.

	Region	Lund
	Country	Sweden
	Organisation	Merck Life Science Business (MilliporeSigma in US)
	Group	Merck (DE) (Group)
	Organisation 2	BioInvent International AB (Nasdaq Stockholm: BINV)
	Product	Mobius® bioreactor (product series)
	Product 2	antibody
	Index term	BioInvent–Merck (DE): bioreactors, 201704 supply full line of Mobius single-use bioreators to BioInvent upstream facility in Lund
	Person	Batra, Udit (Waters 202009– CEO before Merck Life Sciences + Merck Millipore + Novartis + JnJ + McKinsey)

> Sizes range from 3-liter bench-top to 1000-liter manufacturing scale

> Fully scalable system streamlines drug development and production

Merck, a leading science and technology company, today announced that BioInvent International AB, a Swedish company which develops novel immuno-regulatory antibodies to treat cancer, is upgrading and expanding its drug manufacturing facility with a full line of Merck’s Mobius® single-use bioreactors.

BioInvent will add 3-, 50-, 200- and 1000-liter bioreactors to its upstream facility in Lund, Sweden, expanding capacity and improving flexibility and scalability. Merck’s portfolio of 3- to 2000- liter single-use Mobius® bioreactors offers industry-leading benefits that deliver greater flexibility and continuity for scale-up, reducing the need for re-training of operators during scale-up processes.

“Our complete portfolio of single-use technologies addresses the needs of both emerging biopharmaceutical companies and established drug developers like BioInvent as they seek to increase productivity,” said Udit Batra, Member of the Merck Executive Board and CEO of the life science business sector of Merck. “We are providing a full range of bioreactors, services and support which will help BioInvent accelerate innovative therapeutics through the development pipeline.”

The upgrade of the BioInvent facility to include a 1000-liter single-use bioreactor will allow the company to meet production requirements for both its own novel antibody development projects and also those of customers they serve around the world.

“BioInvent has been discovering and manufacturing antibodies for more than 30 years, and when we decided to upgrade our single-use production facility, we established very demanding requirements,” said Kristoffer Rudenholm Hansson, vice president of Technical Operations at BioInvent. “Merck’s single-use bioreactors most effectively addressed our current and future needs with a fully scalable system.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website www.merckgroup.com/media. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Record changed: 2023-06-05